Liposome Technology
SERVICES
- Formulation Development
- Analytical Method Development
- Process Development
- GMP Production
- Filling
- Clinical & Regulatory Support

CLINICAL & REGULATORY SUPPORT
- IMPD / IND, IRB Submission
- Pre-/Clinical Development Concepts
- Organisation of Clinical Studies
- Legal Representative
- Requests For Scientific Advice

TECHNOLOGY
- Full Scalability
- Single Step Process
- Aseptic Process
- Homogeneous, Uniform Vesicles
- Excellent Batch to Batch Consistency
- Mild Procedure – Stability

Polymun Scientific Immunobiologische Forschung GmbH

Liposome Technology
Liposomal Formulation of Drugs

Liposomes protect, transport and release your drug at the right place and time. By this, a reduced dose achieves better efficacy and avoids side effects with a non-invasive application. A liposomal formulation can clearly improve the therapeutic index of your drug.

Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients such as oligonucleotides, small molecules and proteins as well as vaccine antigens. A broad spectrum of analytical methods has been established for this purpose. Polymun produces GMP material including all necessary documentation for IMPD/IND. We assist in planning and implementation of clinical trials. Finally, license agreements are offered for the respective substance on an exclusive basis. Contracts can be arranged step by step - proof of concept, in-depth analysis, GMP production, product license - or all in one.

Different encapsulation techniques are employed, depending on the nature of the drug. Hydrophilic substances are passively entrapped. Amphiphilic substances are actively loaded and hydrophobic drugs or membrane proteins are incorporated into the membrane of the liposomes. Our patented liposome production technology is the key to a high quality solution for a broad range of active ingredients and vaccine antigens.

Alternative to Polymun's own technologies, non-proprietary technologies and existing customer processes can be implemented.

ADVANTAGES OF LIPOSOMAL FORMULATION

PROTECTION. Liposomes shield the drug from degradation. In the body, liposomes prolong the biological half-life.

SOLUBILIZATION. Liposomes can enhance solubility within the aqueous core and the lipid membrane.

TARGETED DRUG DELIVERY. Depending on their lipid composition, liposomes are able to localize, to target and to interact specifically with the affected tissue.

NON-INVASIVE APPLICATION. Liposomes can target the skin and the tissue below. The mucosa is an excellent target for quick uptake of liposomal drug formulations. Alternatively, liposomes can be inhaled in order to target the lung.

SUSTAINED RELEASE / LOW APPLICATION DOSE. Liposomes constitute a depot of the drug resulting in sustained release. Thereby, undesired peak concentrations are avoided and availability is prolonged. This results in a lower frequency of application and the reduction of side effects.

TOXICITY MINIMIZATION. Liposomal formulations are used in cancer treatment for reducing the toxic side effects of the drug.

MILD PROCEDURE ENSURES STABILITY

The crossflow injection technique is a very mild procedure that allows processing of sensitive drugs. High quality raw materials and precisely controllable process parameters guarantee high batch to batch consistency – essential for pharmaceutical products. Consequently, we achieve long term stability of liposomes even at room temperature.

EXCELLENT BATCH TO BATCH CONSISTENCY

POLYMUN LIPOSOMAL PRODUCTS ARE STABLE OVER YEARS
Polymun has transformed liposomes from a promising scientific idea into a sound industrial solution. The production technology is suitable for a broad range of substances formulated by passive entrapment, active loading or membrane incorporation.

**MAIN CHARACTERISTICS OF OUR TECHNOLOGY**

**FULL SCALABILITY**
The injection module is the heart of the liposome production. The process parameters determine the size of the liposomes regardless of the scale. Production of 250 liters of liposome preparation takes only 1.5 hour. Large scale also can be achieved by using several injection modules in parallel.

**ASEPTIC PROCESS**
A closed system is used for production. All components can be added via sterile filtration. Subsequent concentration by crossflow filtration is possible as well.

**HOMOGENEOUS, UNIFORM VESICLES**
All process parameters are controlled precisely. This results in a very narrow size distribution, necessary for reliable targeting and transport characteristics.

**SINGLE STEP PROCESS**
Liposome size is adjusted by modulating the process parameters during vesicle formation. No additional downsizing is required.

**EXCELLENT BATCH TO BATCH CONSISTENCY**
High quality of raw materials and precisely controlled process parameters guarantee excellent reproducibility – essential for pharmaceutical products.

**MILD PROCEDURE – STABILITY**
The crossflow injection technique is a very mild procedure that allows the processing of sensitive drugs. Together with the high quality of raw materials and narrow size distribution, we achieve long term stability of liposomes even at room temperature.

**CGMP PRODUCTION**

**PATENTS**

**Method and device for producing lipid vesicles**
granted by: AU 2002215987, CA 2,427,640; EP 1337322; US 6,843,942

Application of superoxide dismutase in liposomes
granted by: AU 690377, CA 2,204,493; EP 0789584; MX 206929; NZ 294598; US 5,942,245; US 6,312,720

Superloaded liposomes for drug delivery

Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
granted by: AU 04022475.3; EA 011991; EP 1802277; NZ 554183; pending in: CA, CN, IN, JP, KR, US, international stage WO2006042701

**SELECTED PUBLICATIONS**


Polymun’s technology enables the industrial realization of liposomal formulations for pharmaceuticals and medical devices in GMP quality for volumes of 0.5 liters up to cubic meter scale. Product development is performed within the same system at a minimum scale of 20 mL.

LIPOSOMAL FORMULATION IN THE LAB SCALE: 20 mL IN 2 SECONDS

LIPOSOMAL FORMULATION IN THE cGMP PRODUCTION SCALE: 250 L IN 1.5 HOUR
## Reference Projects

<table>
<thead>
<tr>
<th>CUSTOMER/PARTNER</th>
<th>PRODUCT</th>
<th>SCOPE AT POLYMUN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mirna Therapeutics Inc., USA</td>
<td>Liposomal miRNA MRX34 with Smarticle technology for cancer treatment</td>
<td>Process development, GMP production</td>
</tr>
<tr>
<td>Wittycell SAS, France</td>
<td>Liposomal adjuvant WTCc</td>
<td>Formulation and process development, GMP production</td>
</tr>
<tr>
<td>AC Immune SA, Switzerland</td>
<td>ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvant</td>
<td>Process development, GMP production</td>
</tr>
<tr>
<td>EuroNeut-41, EU FP7 project coordinated by Sanofi-Pasteur, France</td>
<td>Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine</td>
<td>Formulation and process development, GMP production</td>
</tr>
<tr>
<td>Signpath Pharma, USA</td>
<td>Liposomal formulation of curcumin for the treatment of cancer</td>
<td>Formulation and process development, GMP production</td>
</tr>
<tr>
<td>ProNAi Inc., USA</td>
<td>Liposomal of DNAi PNT100 with Smarticle technology for cancer treatment</td>
<td>Process development, GMP production</td>
</tr>
<tr>
<td>Dafra Pharma Research and Development bvba, Belgium</td>
<td>OIPC liposomes for the treatment of leishmaniasis</td>
<td>Formulation and process development, GMP production</td>
</tr>
<tr>
<td>Merck Serono, Germany</td>
<td>Survivac, liposomal cancer vaccine</td>
<td>Formulation and process development</td>
</tr>
</tbody>
</table>

www.polymun.com